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In the liver vitamin K epoxide, which is produced uring the posttranslational c rboxylation of protein- 
bound glutamic acid residues, is recycled by the action of one or more dithiol-dependent reductases. In vitro 
synthetic dithiols may serve as a cofactor for these enzymes, but the physiological reductant has not yet 
been found. In this paper we report hat in vitro the commercially available thioredoxin/thioredoxin reduc- 
tase from E. coli can replace the synthetic dithiols during the various reactions of the vitamin K cycle. Based 
on the assumption that in vivo thioredoxin also plays a role in the regeneration fvitamin K hydroquinone 
from the epoxide, an extension of the generally accepted vitamin K cycle is proposed. 
Vitamin K; 7-Carboxyglutamic acid; Thioredoxin; Carboxylase; Warfarin 
1. INTRODUCTION 
Vitamin K-dependent carboxylase is a 
microsomal enzyme system involved in the forma- 
tion of 7-carboxyglutamic acid (Gla) residues 
[1-3]. The energy required for the carboxylation 
reaction is generated by the simultaneous oxida- 
tion of the coenzyme vitamin K hydroquinone 
(KH2) into vitamin K epoxide (KO). The epoxide 
may then be recycled again to the hydroquinone by 
one or more reductases, possibly via vitamin K 
quinone (K) as an intermediate. 
In the literature much confusion exists about the 
number and the nature of the reducing enzyme 
system(s). Dithiol-dependent enzymes have been 
described which convert KO to K [4,5] and K to 
KH2 [6,7] and the question of whether these two 
activities are carried out by the same enzyme has 
not yet been answered satisfactorily. Also, an 
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NADH-  or NADPH-dependent reductase has been 
reported, which is able to generate KH2 from K but 
which cannot recycle KO [8,9]. It has been sug- 
gested [10] that the latter enzyme may be similar to 
the cytosolic DT-diaphorase (EC 1.6.99.2). In con- 
trast to the dithiol-dependent reductases, the 
NAD(P)H-dependent enzyme seems to be insen- 
sitive to vitamin K antagonists of the dicoumarol 
type (warfarin, acenocoumarol, phenprocoumon). 
The concentration of NAD(P)H-dependent reduc- 
tase in washed microsomes is relatively low, 
however. Two conclusions may be drawn from the 
data reported until now: (i) dithiols like 
dithiothreitol are much better cofactors for the in 
vitro reductase(s) than NAD(P)H and (ii) the 
physiological counterpart of these dithiols has not 
yet been identified. '~ 
Thioredoxin is a protein which has been de- 
scribed as acting as a dithiol in many biochemical 
reactions and occurs in organisms differing as 
much as E. coli and mammals [11,12]. Also, in calf 
liver its presence has been established [13]. In its 
oxidized form the protein requires an enzyme nam- 
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ed thioredoxin reductase (EC 1.6.45) and NADPH 
to be converted into its reduced form. In this way 
thioredoxin may be efficiently recycled in vivo. We 
have tested whether the commercially available 
thioredoxin/thioredoxin reductase system from E. 
coli would be able to replace dithiothreitol in the 
carboxylase/reductase enzyme system from bovine 
liver. The results of these experiments are 
presented here. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Vitamin KI, warfarin, dithiothreitol and 
3-([3-cholamidopropylldimethylammonio)- l -pr -  
panesulfonate (CHAPS) were obtained from 
Sigma (St. Louis, USA) and the synthetic penta- 
peptide Phe-Leu-Glu-Glu-Leu (FLEEL) from 
Vega Biochemical (Tucson, USA). Vitamin K1 
epoxide was prepared as in [14]. Thioredoxin and 
thioredoxin reductase were purchased from IMCO 
(Stockholm, Sweden) and NaH14CO3 (40 Ci/mol) 
from Amersham International (England). Atom- 
light was from New England Nuclear (Dreiech, 
FRG) and NADPH from Boehringer (Mannheim). 
All other chemicals were of the highest purity com- 
mercially available. 
2.2. Carboxylase assay 
Salt-washed microsomes and partly purified car- 
boxylase were prepared from the livers of normal 
cows [15]. Unless indicated otherwise, the vitamin 
K-dependent incorporation of 14CO2 was 
measured in reaction mixtures (0.125 ml) contain- 
ing 0.3 mg partly purified carboxylase, 0.15 M 
NaCl, 1 M (NH4)2SO4, 20 mM Tris-HCl, pH 7.5, 
8 mM MnCl2, 5/zCi NaHI4CO3, 4 mM FLEEL, 
0.16% (w/v) CHAPS, 0.4 mg/ml phosphatidyl- 
choline (added as mixed micelles with cholate in a 
1 : 1 (w/w) ratio) and 0.4 mM of either vitamin K 
quinone or vitamin K epoxide. The vitamin was 
solubilized by mixing it with the phosphatidyl- 
choline before preparing the mixed micelles ac- 
cording to De Metz et al. [16]. Dithiothreitol, 
NADPH, thioredoxin and thioredoxin reductase 
were added as indicated. The reaction mixtures 
were incubated at 25°C and the reaction was stop- 
ped by adding 1 ml of 5% (w/v) trichloroacetic 
acid. The samples were subsequently boiled for 
1 min and counted in Atomlight. All measure- 
ments were made in duplicate and mean values are 
given throughout this paper. 
2.3. Other assays 
Protein concentrations were determined 
described by Sedmak and Grossberg [17]. 
as 
3. RESULTS 
The three reactions which give rise to the 
'vitamin K cycle' are depicted in fig. 1. The forma- 
tion of Gla residues occurs in reaction 1 by the en- 
zyme carboxylase, which utilizes vitamin K 
hydroquinone (KH2) as a coenzyme. The progress 
of the reaction may be measured by the incorpora- 
tion of  14CO2 into a suitable substrate. Reactions 
3 + 1 may be measured by starting the sanie car- 
boxylase assay with vitamin K quinone (K) instead 
of KH2. The reduction of K into KH2, which 
precedes the carboxylation reaction, is accomplish- 
ed by K reductase. Either dithiols (e.g. 
dithiothreitol) or NAD(P)H may be used as a 
reducing cofactor, but it was found that at 
saturating concentrations (5 mM) dithiothreitol is
about 20-fold more effective than NADPH. The 
NADPH-driven reaction reaches a plateau level at 
about 2 mM NADPH and the apparent Km for this 
cofactor was calculated to be 0.5 mM. All ex- 
periments described below were performed in the 
absence of dithiothreitol, but in the presence of an 
excess of NADPH, i.e. 20-times the Km value 
(10 mM). 
DTT-S 2 
GLU GLA 
KH 2 ~ KO 
~'o~ K ~'~/ DTT-(SH)2 
DTT- (SH) 2 DTT-S 2 
Fig. 1. The vitamin K cycle. It is generally assumed that 
vitamin K is recycled in the liver by the action of three 
enzymes: carboxylase, KO reductase and K reductase. It 
is not certain whether the two reducing steps are 
accomplished by one or by two enzymes. 
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Since NADPH alone seems to be a poor cofactor 
for vitamin K reductase, we have tried to stimulate 
reactions 1 + 3 by adding the dithiol protein 
thioredoxin and/or the reducing enzyme system 
thioredoxin reductase. As is shown in fig.2 the two 
proteins alone have no effect on the carboxylase 
activity, but the combination of the two proteins 
resulted in a 7-fold stimulation of the NADPH- 
driven carboxylation reaction. The results shown 
in this figure were obtained with partly purified 
carboxylase, but similar data were observed if salt- 
washed solubilized microsomes were used as a 
source of carboxylase (not shown). Under our ex- 
perimental conditions aturating concentrations of 
thioredoxin reductase were reached at 0.6/zM 
(fig.2A) and all experiments described below were 
performed therefore at 1/zM thioredoxin reduc- 
tase. Under these conditions the carboxylase reac- 
tion could be stimulated 7-fold by adding 
thioredoxin (fig.2B). From the data shown in 
fig.2B we have calculated the apparent Km for 
thioredoxin, which was 20/~M. For the rest of our 
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Fig.2. Effects of thioredoxin reductase and thioredoxin 
on the carboxylation reaction. All reaction mixtures 
contained vitamin K quinone as a sole source of vitamin 
K and were incubated for 1 h at 25°C. (A) Increasing 
amounts of thioredoxin reductase were added to 
standard reaction mixtures containing 150/zM 
thioredoxin. (B) Increasing amounts of thioredoxin were 
added to standard reaction mixtures containing 1/zM 
thioredoxin reductase. All experiments were performed 
in the presence (closed symbols) and absence (open 
symbols) of 10 mM NADPH. 
experiments we have worked at a thioredoxin con- 
centration of 150 #M. 
To investigate reactions 1 + 2 + 3 (fig.l) in one 
system, the carboxylation reaction has to be 
started with vitamin K epoxide (KO). We have 
checked if the thioredoxin/thioredoxin reductase 
system could be used as a sole source of reducing 
cofactor (thioredoxin-(SH)2) for both vitamin K 
reductases. The results of these experiments are 
summarized in table 1 and it is clear that all reac- 
tions of the vitamin K cycle are catalyzed by the 
thioredoxin/thioredoxin reductase system. More- 
over, in the presence of KO as well as in that of K 
the thioredoxin-stimulated r action rate amounted 
to about 40°70 of that of the DTT-stimulated one. 
It is well known that vitamin K antagonists (war- 
farin) inhibit the DTT-dependent K and KO reduc- 
tases and not the NADH-dependent K reductase. 
We have determined to what extent the 
thioredoxin-dependent KO and K reductase ac- 
tivities were inhibited by warfarin. As shown in 
table 2 the KO-dependent carboxylation reaction is 
completely inhibited by 10/~M warfarin thus in- 
dicating that also with thioredoxin-(SH)2 as a 
cofactor, KO reductase is inhibited by vitamin K 
antagonists. A similar concentration also inhibited 
the main part of the K-dependent carboxylation 
Table 1 
Peptide carboxylation in the presence of various 
cofactors 
Cofactors used Initial carboxylation 
rate (dpm per rain) 
K + DTT 2173 
K + NADPH 106 
K + NADPH + thioredoxin 857 
KO ÷ DTT 1601 
KO + NADPH 22 
KO + NADPH + thioredoxin 645 
In the cases in which thioredoxin-(SH)2 was used, 
thioredoxin reductase (1/~M) was also present in the 
reaction mixtures. The initial carboxylation rates were 
obtained from time course experiments and were 
constant for the first 30 min or more. Results are 
expressed as the amount of 14CO2 (dpm) incorporated 
per min under our experimental conditions. Blank values 
(obtained in the absence of either K or KO) were 
subtracted 
355 
Volume 222, number 2 FEBS LETTERS October 1987 
GLII GLA 
KH 7 D KO 
CARBOXYLASF 
NADPH+H+ , ~\-% , .~/ /  z NADP 
%\\ I < ~ lh" 
NADP + NADPH+H + 
Fig.3. Proposed extension of the vitamin K cycle. The 
synthetic dithiols from .fig.] have been replaced by 
thioredoxin-(SH)2 and the thioredoxin-(SH)2 generating 
system (thioredoxin reductase + NADPH). TR, 
thioredoxin. 
reaction, but a residual activity of about 7°7o was 
found, even if the warfarin concentration was 
raised to 0.1 mM. A comparable activity was 
obtained in the absence of thioredoxin and thiore- 
doxin reductase, so that we must conclude that the 
warfarin-insensitive activity originates from the 
NADH-dependent K reductase, which has been 
reported earlier to be insensitive for coumarin 
derivatives [9]. 
4. DISCUSSION 
In vitro the conversion of vitamin KO to vitamin 
K has been shown to be absolutely dependent on 
synthetic dithiols such as dithiothreitol [2]. Also, 
for the reduction of vitamin K the dithiol- 
dependent reductase is by far the most effective n- 
zyme system [14]. Although KO reductase was 
discovered more than 10 years ago [19], the 
physiological counterpart of its in vitro cofactor 
has never been discovered. 
Here, we have shown that the thioredox- 
in/thioredoxin reductase from E. coli is able to 
replace dithiothreitol during the in vitro carboxyla- 
tion reaction. The activity obtained was about 
40°7o of that in the presence of dithiothreitol. These 
experiments indicate that possibly the thioredox- 
in/thioredoxin reductase system is the 
physiological system which produces the reducing 
equivalents required for the reduction of vitamin 
KO and vitamin K in vivo. It is not unlikely that 
the thioredoxin/thioredoxin reductase system 
from bovine liver will prove to be an even more ef- 
fective system for bovine liver carboxylase, since a 
substantial species specificity of thioredoxin has 
been reported [12]. In fact it is surprising that 
bovine vitamin KO reductase and vitamin K reduc- 
tase both recognize E. coli thioredoxin-(SH)2. 
Based on our experiments we postulate an exten- 
sion of the vitamin K cycle in which the oxidation 
of dithiothreitol is replaced by that of thioredoxin, 
whereas the oxidized thioredoxin is recycled via 
thioredoxin reductase + NADPH (fig.3). 
A practical aspect of our findings is that the 
thioredoxin/thioredoxin reductase provides a good 
alternative for the strongly reducing conditions 
(caused by the synthetic dithiols) during the in 
vitro carboxylation of disulfide-containing 
substrates. This opens up the possibility of starting 
experiments in which protein substrates uch as 
blood coagulation factor precursors [either present 
as an endogenous substrate complexed to carbox- 
ylase from warfarin-treated animals or added as an 
exogenous substrate (e.g. obtained via recom- 
binant-DNA technology)] are carboxylated in vitro 
without reducing the disulfide bonds in these pro- 
teins. This is a first requirement before the in vitro 
carboxylation of, for instance, blood coagulation 
factor IX precursors may be expected to increase 
the procoagulant activity of this protein. 
Table 2 
Inhibition of peptide carboxylation by warfarin 
Cofactors used Warfarin Initial carboxyl- 
concentration ation rate 
(mM) (dpm per min) 
K 0 203 
K + thioredoxin 0 1840 
K 0.01 137 
K + thioredoxin 0.01 138 
KO 0 13 
KO + thioredoxin 0 1556 
KO 0.01 0 
KO + thioredoxin 0.01 9 
All reaction mixtures contained 10 mM NADPH. In 
those cases in which thioredoxin was used, thioredoxin 
reductase (l/~M) was also present in the reaction 
mixtures. Further details as described in the legend to 
table l 
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